Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer (RUBY Trial)
Source: View publication →
In patients with primary advanced or recurrent endometrial cancer, the addition of the PD-1 inhibitor dostarlimab to standard-of-care carboplatin-paclitaxel chemotherapy significantly improves both progression-free and overall survival compared to chemotherapy alone.
Key Findings
Study Design
Study Limitations
Clinical Significance
The RUBY trial establishes a new frontline standard-of-care for patients with advanced or recurrent endometrial cancer, marking the first time an immune-checkpoint inhibitor combined with chemotherapy has demonstrated a clear overall survival benefit in this population.
Historical Context
For decades, platinum-based chemotherapy (carboplatin and paclitaxel) served as the primary systemic treatment for advanced endometrial cancer, with limited options available following disease progression. The RUBY trial represents a paradigm shift by integrating PD-1 blockade into the frontline setting, building on previous success with single-agent checkpoint inhibitors in later lines of therapy.
Guided Discussion
High-yield insights from every perspective
How does a deficiency in DNA mismatch repair (dMMR) lead to an increased sensitivity to PD-1 inhibitors like dostarlimab in endometrial cancer?
Key Response
dMMR leads to the accumulation of numerous mutations (high tumor mutational burden), which results in the production of neoantigens. These neoantigens make the tumor more 'visible' to the immune system. Dostarlimab blocks the PD-1 receptor on T-cells, preventing the tumor from using the PD-L1 pathway to evade immune detection, thereby allowing the sensitized T-cells to attack the neoantigen-rich cancer cells.
In a patient with newly diagnosed Stage IV endometrial cancer that is mismatch repair proficient (pMMR), how do the RUBY trial results influence your decision to add dostarlimab to standard carboplatin-paclitaxel?
Key Response
The RUBY trial demonstrated a statistically significant improvement in progression-free survival (PFS) for the overall population, including the pMMR subgroup (HR 0.76). While the benefit is most dramatic in dMMR patients (HR 0.28), the resident must recognize that adding dostarlimab is now a valid consideration for pMMR patients, though they should also weigh the benefit against potential immune-related adverse events and alternative regimens like pembrolizumab/lenvatinib.
The RUBY trial utilized a dual primary endpoint of PFS in the dMMR/MSI-H population and PFS in the overall population. How does this hierarchical testing strategy impact the interpretation of the results for the pMMR cohort?
Key Response
By using a hierarchical or 'gatekeeping' strategy, the study ensures that the statistical significance in the overall population (which includes pMMR) is only formally tested if the dMMR population reaches significance. This protects the type I error rate. For a fellow, understanding that the overall population's success was driven largely by the dMMR effect size is crucial when discussing the relative magnitude of benefit in the pMMR subgroup.
Given the survival benefit seen in RUBY, how should the timing of molecular testing for MMR/MSI status be optimized in clinical practice to ensure appropriate first-line therapy?
Key Response
The RUBY results shift immunotherapy from the second-line (recurrent) setting to the first-line (primary advanced) setting. Therefore, universal MMR testing via IHC or NGS should be performed at the time of initial diagnosis or first biopsy of advanced disease, rather than waiting for recurrence, to ensure that the window for maximum benefit from dostarlimab plus chemotherapy is not missed.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
What are the limitations of using the RECIST v1.1 criteria to evaluate progression-free survival in a trial combining cytotoxic chemotherapy with a PD-1 inhibitor, and how might 'pseudoprogression' affect the RUBY trial's primary endpoint analysis?
Key Response
RECIST v1.1 may classify early immune-cell infiltration into the tumor as 'progression' (pseudoprogression), potentially underestimating the true clinical benefit of immunotherapy. While cytotoxic chemotherapy usually induces rapid shrinkage, the immune component may cause transient flares. Researchers often use iRECIST in exploratory analyses to account for this, ensuring that patients are not prematurely removed from a potentially beneficial therapy.
While the RUBY trial shows clear efficacy, what concerns regarding the 'standard of care' control arm might a reviewer raise given the concurrent development of other checkpoint inhibitor combinations like NRG-GY018?
Key Response
An editor would look for whether the control arm (carboplatin-paclitaxel alone) remained the true global standard throughout the trial's duration and how the RUBY data compares to the nearly simultaneous NRG-GY018 (pembrolizumab) results. They would flag the need for a discussion on cross-trial comparisons and whether the trial sufficiently addressed PD-L1 expression levels as a predictive biomarker versus MMR status alone.
Should the RUBY trial data prompt a change in the NCCN Guidelines to make dostarlimab plus carboplatin-paclitaxel a 'Preferred' Category 1 recommendation for dMMR primary advanced endometrial cancer?
Key Response
Yes. Prior to RUBY, the standard was chemotherapy alone, with immunotherapy reserved for second-line. Given the hazard ratio for PFS of 0.28 and an early signal of improved overall survival in the dMMR group, the evidence meets the criteria for Category 1. The committee must decide if the benefit in the pMMR group (HR 0.76) is strong enough to warrant a similar 'Preferred' status or if it should be a 'Specified Circumstance' recommendation.
Clinical Landscape
Noteworthy Related Trials
GOG-258 Trial
Tested
Chemotherapy plus radiotherapy
Population
Stage III or IV endometrial cancer
Comparator
Chemotherapy alone
Endpoint
Recurrence-free survival
KEYNOTE-158 Trial
Tested
Pembrolizumab monotherapy
Population
Previously treated mismatch repair-deficient endometrial cancer
Comparator
None (Single-arm)
Endpoint
Objective response rate
NRG-GY018 Trial
Tested
Pembrolizumab plus chemotherapy
Population
Advanced or recurrent endometrial cancer
Comparator
Placebo plus chemotherapy
Endpoint
Progression-free survival
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis